AP5346

AP5346 (ProLindac) is a third-generation polymer-conjugated platinum-based chemotherapeutic agent designed for the treatment of various cancers. It consists of diaminocyclohexane (DACH)-platinum—the active moiety in oxaliplatin—covalently bound to a water-soluble hydroxypropylmethacrylamide (HPMA) copolymer via a pH-sensitive linker. This design enables targeted delivery and controlled release of the cytotoxic platinum compound preferentially within the acidic microenvironment typical of tumors. The mechanism involves DNA binding and crosslinking, leading to inhibition of DNA replication and transcription, ultimately triggering apoptosis in cancer cells. Preclinical and clinical studies have shown efficacy at least equal to or superior to oxaliplatin with improved tolerability. The drug was developed by Abeona Therapeutics and reached phase II clinical trials for solid tumors including recurrent ovarian cancer but has since been discontinued[1][3][4][5].

Brand names

ProLindac

Other names

DACH polymer platinateDACH platinum polymer prodrug